Clinical course in Parkinson's disease with elevated homocysteine.
Elevated homocysteine (Hcy), prevalent in Parkinson's disease (PD), is potentially a modifiable risk factor for neurologic deterioration. We measured cognitive, affective and motor changes over 2 years in a cohort of people with early PD. Subjects whose Hcy had been elevated (>14 micromol/L, n = 31) at baseline were compared with the rest (n = 66). Overall progression in 2 years did not significantly differ (p = 0.20). Four subjects with elevated and one with normal Hcy had died (p = 0.03). We conclude that hyperhomocysteinemia does not predict significantly worse progression over 2 years in early PD. The data raised the possibility of higher mortality, but the number of deaths was small.
O'Suilleabhain
Padraig E
PE
Department of Neurology, Southwestern Medical Center at Dallas, University of Texas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9036, USA. padraig.osuilleabhain@utsouthwestern.edu
Oberle
Robert
R
Bartis
Cristina
C
Dewey
Richard B
RB
Bottiglieri
Teodoro
T
Diaz-Arrastia
Ramon
R
D000339:Affect / Q000502:physiology; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D003071:Cognition / Q000502:physiology; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009068:Movement / Q000502:physiology; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000097:blood* / Q000503:physiopathology* / Q000523:psychology; D012307:Risk Factors; D014803:Vitamin B Complex / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D015415:Biomarkers; D014815:Vitamins; D006710:Homocysteine; D014803:Vitamin B Complex